View Item 

Show simple item record

Review of Opioid Pharmacogenetics and Considerations for Pain Management
dc.contributor.authorOwusu Obeng, Aniwaa
dc.contributor.authorHamadeh, Issam
dc.contributor.authorSmith, Michael
dc.date.accessioned2017-10-05T18:17:40Z
dc.date.available2018-12-03T15:34:02Zen
dc.date.issued2017-09
dc.identifier.citationOwusu Obeng, Aniwaa; Hamadeh, Issam; Smith, Michael (2017). "Review of Opioid Pharmacogenetics and Considerations for Pain Management." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37(9): 1105-1121.
dc.identifier.issn0277-0008
dc.identifier.issn1875-9114
dc.identifier.urihttps://hdl.handle.net/2027.42/138276
dc.publisherWiley Periodicals, Inc.
dc.subject.othertoxicity
dc.subject.othersafety
dc.subject.otherpersonalized pain management
dc.subject.otherpersonalized dosing
dc.subject.otherefficacy
dc.subject.otherpharmacogenetics
dc.subject.otheropioids
dc.titleReview of Opioid Pharmacogenetics and Considerations for Pain Management
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138276/1/phar1986_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138276/2/phar1986.pdf
dc.identifier.doi10.1002/phar.1986
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
dc.identifier.citedreferenceZwisler ST, Enggaard TP, Mikkelsen S, et al. Lack of association of OPRM1 and ABCB1 single‐nucleotide polymorphisms to oxycodone response in postoperative pain. J Clin Pharmacol 2012; 52 ( 2 ): 234 – 42.
dc.identifier.citedreferenceSia AT, Lim Y, Lim EC, et al. A118G single nucleotide polymorphism of human mu‐opioid receptor gene influences pain perception and patient‐controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008; 109 ( 3 ): 520 – 6.
dc.identifier.citedreferenceHolthe M, Klepstad P, Zahlsen K, et al. Morphine glucuronide‐to‐morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur J Clin Pharmacol 2002; 58 ( 5 ): 353 – 6.
dc.identifier.citedreferenceDarbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J. UGT2B7 promoter variant ‐840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 2008; 83 ( 3 ): 200 – 2.
dc.identifier.citedreferenceNaito T, Takashina Y, Yamamoto K, et al. CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. J Clin Pharmacol 2011; 51 ( 11 ): 1529 – 38.
dc.identifier.citedreferenceAndreassen TN, Eftedal I, Klepstad P, et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross‐sectional multicentre study. Eur J Clin Pharmacol 2012; 68 ( 1 ): 55 – 64.
dc.identifier.citedreferenceZwisler ST, Enggaard TP, Mikkelsen S, Brosen K, Sindrup SH. Impact of the CYP2D6 genotype on post‐operative intravenous oxycodone analgesia. Acta Anaesthesiol Scand 2010; 54 ( 2 ): 232 – 40.
dc.identifier.citedreferenceSamer CF, Daali Y, Wagner M, et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol 2010; 160 ( 4 ): 907 – 18.
dc.identifier.citedreferenceStamer UM, Zhang L, Book M, Lehmann LE, Stuber F, Musshoff F. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. PLoS ONE 2013; 8 ( 3 ): e60239.
dc.identifier.citedreferenceOtton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53 ( 4 ): 401 – 9.
dc.identifier.citedreferenceCajanus K, Kaunisto MA, Tallgren M, Jokela R, Kalso E. How much oxycodone is needed for adequate analgesia after breast cancer surgery: effect of the OPRM1 118A>G polymorphism. J Pain 2014; 15 ( 12 ): 1248 – 56.
dc.identifier.citedreferenceStamer UM, Musshoff F, Kobilay M, Madea B, Hoeft A, Stuber F. Concentrations of tramadol and O‐desmethyltramadol enantiomers in different CYP2D6 genotypes. Clin Pharmacol Ther 2007; 82 ( 1 ): 41 – 7.
dc.identifier.citedreferencePedersen RS, Damkier P, Brosen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol 2006; 62 ( 7 ): 513 – 21.
dc.identifier.citedreferenceGan SH, Ismail R, Wan Adnan WA, Zulmi W. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. Mol Diagn Ther 2007; 11 ( 3 ): 171 – 81.
dc.identifier.citedreferenceStamer UM, Stuber F, Muders T, Musshoff F. Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication. Anest Analg 2008; 107 ( 3 ): 926 – 9.
dc.identifier.citedreferenceLiu YC, Wang WS. Human mu‐opioid receptor gene A118G polymorphism predicts the efficacy of tramadol/acetaminophen combination tablets (ultracet) in oxaliplatin‐induced painful neuropathy. Cancer 2012; 118 ( 6 ): 1718 – 25.
dc.identifier.citedreferenceIolascon A, Faienza MF, Centra M, Storelli S, Zelante L, Savoia A. (TA)8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert’s syndrome. Haematologica 1999; 84 ( 2 ): 106 – 9.
dc.identifier.citedreferenceBeutler E, Gelbart T, Demina A. Racial variability in the UDP‐glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95 ( 14 ): 8170 – 4.
dc.identifier.citedreferenceKlepstad P, Fladvad T, Skorpen F, et al. Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 2011; 152 ( 5 ): 1139 – 45.
dc.identifier.citedreferenceRakvag TT, Ross JR, Sato H, Skorpen F, Kaasa S, Klepstad P. Genetic variation in the catechol‐O‐methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 2008; 4: 64.
dc.identifier.citedreferenceMadadi P, Sistonen J, Silverman G, et al. Life‐threatening adverse events following therapeutic opioid administration in adults: is pharmacogenetic analysis useful? Pain Res Manage 2013; 18 ( 3 ): 133 – 6.
dc.identifier.citedreferenceU.S. Food and Drug Administration. FDA Drug Safety Communication: Safety review update of codeine use in children; new Boxed Warning and Contraindication on use after tonsillectomy and/or adenoidectomy. Rockville, MD [updated 1/15/2016]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm339112.htm. Accessed November 1, 2016.
dc.identifier.citedreferenceRelling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015; 526 ( 7573 ): 343 – 50.
dc.identifier.citedreferenceDavis MP, Walsh D. Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp Palliat Care 2004; 21 ( 2 ): 137 – 42.
dc.identifier.citedreferenceApfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anest Analg 2003; 97 ( 2 ): 534 – 40, table of contents.
dc.identifier.citedreferenceMadadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case‐control study. Clin Pharmacol Ther 2009; 85 ( 1 ): 31 – 5.
dc.identifier.citedreferenceTakashina Y, Naito T, Mino Y, Yagi T, Ohnishi K, Kawakami J. Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet 2012; 27 ( 4 ): 414 – 21. PubMed PMID: 22277678.
dc.identifier.citedreferenceKoren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine‐prescribed mother. Lancet 2006; 368 ( 9536 ): 704.
dc.identifier.citedreferenceSusce MT, Murray‐Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30 ( 7 ): 1356 – 8.
dc.identifier.citedreferenceTrescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain physician 2008; 11 ( 2 Suppl ): S133 – 53. PubMed PMID: 18443637.
dc.identifier.citedreferenceMeyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356 ( 9242 ): 1667 – 71.
dc.identifier.citedreferenceGalley HF, Mahdy A, Lowes DA. Pharmacogenetics and anesthesiologists. Pharmacogenomics 2005; 6 ( 8 ): 849 – 56.
dc.identifier.citedreferenceZhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009; 48 ( 11 ): 689 – 723.
dc.identifier.citedreferenceKirchheiner J, Keulen JT, Bauer S, Roots I, Brockmoller J. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol 2008; 28 ( 1 ): 78 – 83.
dc.identifier.citedreferenceEckhardt K, Li S, Ammon S, Schanzle G, Mikus G, Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998; 76 ( 1–2 ): 27 – 33.
dc.identifier.citedreferenceBrousseau DC, McCarver DG, Drendel AL, Divakaran K, Panepinto JA. The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J Pediatr 2007; 150 ( 6 ): 623 – 6.
dc.identifier.citedreferenceVanderVaart S, Berger H, Sistonen J, et al. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. Ther Drug Monit 2011; 33 ( 4 ): 425 – 32.
dc.identifier.citedreferenceBaber M, Chaudhry S, Kelly L, et al. The pharmacogenetics of codeine pain relief in the postpartum period. Pharmacogenomics J 2015; 15 ( 5 ): 430 – 5.
dc.identifier.citedreferenceShaw KD, Amstutz U, Jimenez‐Mendez R, Ross CJ, Carleton BC. Suspected opioid overdose case resolved by CYP2D6 genotyping. Ther Drug Monit 2012; 34 ( 2 ): 121 – 3.
dc.identifier.citedreferenceVoronov P, Przybylo HJ, Jagannathan N. Apnea in a child after oral codeine: a genetic variant ‐ an ultra‐rapid metabolizer. Paediatr Anaesth 2007; 17 ( 7 ): 684 – 7.
dc.identifier.citedreferenceCrews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 2012; 91 ( 2 ): 321 – 6.
dc.identifier.citedreferenceCrews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 2014; 95 ( 4 ): 376 – 82.
dc.identifier.citedreferenceU.S. Food and Drug Administration. FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. 2017.
dc.identifier.citedreferenceLandau R, Liu SK, Blouin JL, Carvalho B. The effect of OPRM1 and COMT genotypes on the analgesic response to intravenous fentanyl labor analgesia. Anest Analg 2013; 116 ( 2 ): 386 – 91.
dc.identifier.citedreferenceFukuda K, Hayashida M, Ide S, et al. Association between OPRM1 gene polymorphisms and fentanyl sensitivity in patients undergoing painful cosmetic surgery. Pain 2009; 147 ( 1–3 ): 194 – 201.
dc.identifier.citedreferenceHayashida M, Nagashima M, Satoh Y, et al. Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 2008; 9 ( 11 ): 1605 – 16.
dc.identifier.citedreferenceGinosar Y, Davidson EM, Meroz Y, Blotnick S, Shacham M, Caraco Y. Mu‐opioid receptor (A118G) single‐nucleotide polymorphism affects alfentanil requirements for extracorporeal shock wave lithotripsy: a pharmacokinetic‐pharmacodynamic study. Br J Anaesth 2009; 103 ( 3 ): 420 – 7.
dc.identifier.citedreferenceStauble ME, Moore AW, Langman LJ, et al. Hydrocodone in postoperative personalized pain management: pro‐drug or drug? Clin Chim Acta 2014; 429: 26 – 9.
dc.identifier.citedreferenceBoswell MV, Stauble ME, Loyd GE, et al. The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone. Pain Physician 2013; 16 ( 3 ): E227 – 35.
dc.identifier.citedreferenceMadadi P, Hildebrandt D, Gong IY, et al. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. Pediatrics 2010; 126 ( 4 ): e986 – 9.
dc.identifier.citedreferenceZanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet 2013; 4: 24.
dc.identifier.citedreferenceGadel S, Friedel C, Kharasch ED. Differences in Methadone Metabolism by CYP2B6 Variants. Drug Metab Dispos 2015; 43 ( 7 ): 994 – 1001.
dc.identifier.citedreferenceCrettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80 ( 6 ): 668 – 81.
dc.identifier.citedreferenceKharasch ED, Regina KJ, Blood J, Friedel C. Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism. Anesthesiology 2015; 123 ( 5 ): 1142 – 53.
dc.identifier.citedreferenceKirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra‐rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 2007; 7 ( 4 ): 257 – 65.
dc.identifier.citedreferenceCampa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83 ( 4 ): 559 – 66.
dc.identifier.citedreferenceCoulbault L, Beaussier M, Verstuyft C, et al. Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther 2006; 79 ( 4 ): 316 – 24.
dc.identifier.citedreferenceSadhasivam S, Chidambaran V, Zhang X, et al. Opioid‐induced respiratory depression: ABCB1 transporter pharmacogenetics. Pharmacogenomics J 2015; 15 ( 2 ): 119 – 26.
dc.identifier.citedreferenceReyes‐Gibby CC, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007; 130 ( 1–2 ): 25 – 30.
dc.identifier.citedreferenceRakvag TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol‐O‐methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005; 116 ( 1–2 ): 73 – 8.
dc.identifier.citedreferenceMatic M, Simons SH, van Lingen RA, et al. Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype. Pharmacogenomics 2014; 15 ( 10 ): 1287 – 95.
dc.identifier.citedreferenceGong XD, Wang JY, Liu F, et al. Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain. Asian Pac J Cancer Prev 2013; 14 ( 5 ): 2937 – 43.
dc.identifier.citedreferenceKlepstad P, Rakvag TT, Kaasa S, et al. The 118 A > G polymorphism in the human mu‐opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004; 48 ( 10 ): 1232 – 9.
dc.identifier.citedreferenceChou WY, Yang LC, Lu HF, et al. Association of mu‐opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006; 50 ( 7 ): 787 – 92.
dc.identifier.citedreferenceLotsch J, Zimmermann M, Darimont J, et al. Does the A118G polymorphism at the mu‐opioid receptor gene protect against morphine‐6‐glucuronide toxicity? Anesthesiology 2002; 97 ( 4 ): 814 – 9.
dc.identifier.citedreferenceChou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient‐controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006; 105 ( 2 ): 334 – 7.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phar1986_am.pdf
Size:
823.3KB
Format:
PDF
View/Open
Name:
phar1986.pdf
Size:
229.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.